IgA肾病治疗:呼唤新范式
IgA肾病是全球最常见的原发性肾小球疾病,终生肾衰竭风险高且社会经济负担巨大。既往治疗聚焦于优化支持治疗(阻断肾素-血管紧张素系统、控制血压和生活方式调整),免疫抑制尤其是大剂量糖皮质激素的疗效报道不一且严重不良反应证据充分。随着对发病机制的理解加深及监管机构接受蛋白尿和2-3年eGFR下降或斜率作为替代终点,多种新疗法正在评估中,其中SGLT2抑制剂、sparsentan、nefecon和iptacopan已获批。本综述提出联合不同作用机制的治疗新范式,同时靶向免疫成分和CKD成分以保护长期肾脏存活。
要点
- IgA肾病需联合靶向免疫成分与CKD成分的新治疗范式。
- 监管机构已接受蛋白尿和2-3年eGFR下降或斜率作为替代终点。
- SGLT2抑制剂、sparsentan、nefecon和iptacopan已获批用于IgA肾病。
核心结论
- 提出联合不同作用机制的治疗新范式,同时靶向IgA肾病的免疫成分和慢性肾脏病成分,以保护长期肾脏存活。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
主要发现
- 既往支持治疗包括阻断肾素-血管紧张素系统、控制血压和生活方式调整。
- 免疫抑制尤其大剂量糖皮质激素的疗效报道不一,且有相当证据显示严重不良反应增加。
- 多种新疗法正在IgA肾病中评估,SGLT2抑制剂、sparsentan、nefecon和iptacopan已获批。
关键数值与推荐
- 监管机构接受蛋白尿变化和2至3年eGFR下降或斜率作为替代结局标志物。
临床怎么用
- 在支持治疗基础上,可考虑联合不同作用机制药物,同时针对免疫和CKD成分进行管理。
局限性
- 综述未报告系统检索策略、纳入研究数量及样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA nephropathy (IgAN), the world's most common primary glomerular disease, carries a significant lifetime risk for kidney failure as well as an enormous socioeconomic burden. In the past, studies in patients with IgAN largely focused on optimizing so-called supportive care, that is, blockade of the renin-angiotensin system, blood pressure control, and lifestyle modifications. The effectiveness of immunosuppressive measures, particularly high-dose corticosteroid therapy, has been reported variably, but there is considerable evidence for an increase in serious adverse effects with such therapies. This disappointing situation has changed dramatically with a better understanding of the pathogenesis of IgAN, and with regulatory agencies accepting changes in proteinuria and the estimated glomerular filtration rate loss or slope over 2 to 3 years as surrogate outcome markers. A multitude of new therapies are now being evaluated in IgAN, and several drugs, such as sodium-glucose transporter-2 inhibitors, sparsentan (a dual endothelin-1 and angiotensin II receptor blocker), nefecon (a targeted release formulation of budesonide), and iptacopan (a complement factor B inhibitor), have been approved, with more to come in the next few years. In this review, we propose a new treatment paradigm that combines therapies with different mechanisms of action to target the immune components and the chronic kidney disease components of IgAN in parallel to preserve long-term kidney survival.
引用
- Floege J, Bernier-Jean A, Barratt J, et al. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025. PMID: 39894081. doi:10.1016/j.kint.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。